274 related articles for article (PubMed ID: 25975389)
1. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
Kim NY; Lee HY; Lee C
Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.
Suh YA; Jo SY; Lee HY; Lee C
Int J Oncol; 2015 Mar; 46(3):1405-11. PubMed ID: 25544427
[TBL] [Abstract][Full Text] [Related]
3. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.
Lee YJ; Lim T; Han MS; Lee SH; Baek SH; Nan HY; Lee C
Oncol Rep; 2017 Feb; 37(2):1219-1226. PubMed ID: 28035396
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
5. Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells.
Kim NY; Suh YA; Kim S; Lee C
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32219334
[TBL] [Abstract][Full Text] [Related]
6. Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells.
Kim KC; Baek SH; Lee C
Int J Oncol; 2015 Dec; 47(6):2296-303. PubMed ID: 26498137
[TBL] [Abstract][Full Text] [Related]
7. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
[TBL] [Abstract][Full Text] [Related]
9. Mistletoe (Viscum album) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells.
Kim S; Kim KC; Lee C
Phytomedicine; 2017 Dec; 36():183-193. PubMed ID: 29157814
[TBL] [Abstract][Full Text] [Related]
10. Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.
Corno C; Gatti L; Arrighetti N; Carenini N; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2017 Jul; 136():40-50. PubMed ID: 28404378
[TBL] [Abstract][Full Text] [Related]
11. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
[TBL] [Abstract][Full Text] [Related]
12. Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase.
Saito T; Itoh M; Tohda S
Leuk Res; 2020 Jul; 94():106383. PubMed ID: 32460059
[TBL] [Abstract][Full Text] [Related]
13. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells.
Al Kafri N; Hafizi S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664510
[TBL] [Abstract][Full Text] [Related]
15. Axl receptor tyrosine kinase is a novel target of apigenin for the inhibition of cell proliferation.
Kim KC; Choi EH; Lee C
Int J Mol Med; 2014 Aug; 34(2):592-8. PubMed ID: 24926787
[TBL] [Abstract][Full Text] [Related]
16. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells.
Lee YJ; Kim SY; Lee C
Mol Med Rep; 2019 Apr; 19(4):3230-3236. PubMed ID: 30816529
[TBL] [Abstract][Full Text] [Related]
17. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
Sinha S; Boysen J; Nelson M; Secreto C; Warner SL; Bearss DJ; Lesnick C; Shanafelt TD; Kay NE; Ghosh AK
Clin Cancer Res; 2015 May; 21(9):2115-26. PubMed ID: 25673699
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
[TBL] [Abstract][Full Text] [Related]
19. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV
PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
